The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND/AIMS Liver biopsy for hepatocellular carcinoma (HCC) detection is largely restricted to small hepatocellular lesions, which are often morphologically challenging, requiring careful distinction between dysplastic nodules (high-grade) and well-differentiated HCC. METHODS We investigated the diagnostic accuracy of a panel of markers (HSP70 GPC3 and GS), previously tested in resection specimens, in a series of liver biopsies of large regenerative nodules (n=13), low-grade dysplastic nodules (n=21), high-grade dysplastic nodules (n=50), very well-differentiated (VWD) (n=17), well-differentiated (WD-G1) (n=40) and G2-3 (n=35) HCC. RESULTS Almost all cases of large regenerative and low-grade dysplastic nodules did not stain while high-grade dysplastic nodules showed 1 marker (22%) but never 2 or 3. For HCC detection the overall accuracy of marker combination was 60.8% (3 markers) and 78.4% (2 markers) with 100% specificity. When restricted to VWD+WD-G1 HCC the accuracy was 57% (3 markers) and 72.9% (2 markers) with 100% specificity. CONCLUSIONS This panel proved useful to detect well-differentiated HCC in biopsy. Two immunoreactive markers (out of 3) are recommended as the most valuable diagnostic combination for HCC detection. The diagnostic accuracy of the panel could be improved using additional markers, as suggested by studies of expression profiling in other human models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., Wilhelm, S., Lynch, M., & Carter, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1377 · Cited by 1,536
Forner, A., Vilana, R., Ayuso, C., Bianchi, L., Solé, M., Ayuso, J. R., Boix, L., Sala, M., Varela, M., Llovet, J. M., et al. (2008) · Hepatology · doi:10.1002/hep.21966 · Cited by 1,032
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma
Capurro, M., Wanless, I. R., Sherman, M., Deboer, G., Shi, W., Miyoshi, E., & Filmus, J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00689-9 · Cited by 917
Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry
Bioulac-Sage, P., Rebouissou, S., Thomas, C., Blanc, J.-F., Saric, J., Sa Cunha, A., Rullier, A., Cubel, G., Couchy, G., Imbeaud, S., et al. (2007) · Hepatology · doi:10.1002/hep.21743 · Cited by 590 · cited 1×
“Interestingly enough, hepatocellular adenoma undergoing malignant transformation may show GS overexpression as well as b-catenin mutations [21].”
BackgroundDi Tommaso, L., Franchi, G., Park, Y. N., Fiamengo, B., Destro, A., Morenghi, E., Montorsi, M., Torzilli, G., Tommasini, M., Terracciano, L., et al. (2007) · Hepatology · doi:10.1002/hep.21531 · Cited by 427
Self-citationLlovet, J. M., Chen, Y., Wurmbach, E., Roayaie, S., Fiel, M. I., Schwartz, M., Thung, S. N., Khitrov, G., Zhang, W., Villanueva, A., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.014 · Cited by 386
The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma
Yamauchi, N., Watanabe, A., Hishinuma, M., Ohashi, K.-I., Midorikawa, Y., Morishita, Y., Niki, T., Shibahara, J., Mori, M., Makuuchi, M., et al. (2005) · Modern Pathology · doi:10.1038/modpathol.3800436 · Cited by 338
Chuma, M., Sakamoto, M., Yamazaki, K., Ohta, T., Ohki, M., Asaka, M., & Hirohashi, S. (2003) · Hepatology · doi:10.1053/jhep.2003.50022 · Cited by 294
Cholestasis is a marker for hepatocellular carcinomas displaying β‐catenin mutations
Audard, V, Grimber, G., Elie, C., Radenen, B., Audebourg, A., Letourneur, F., Soubrane, O., Vacher‐Lavenu, M., Perret, C., Cavard, C., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2169 · Cited by 162 · cited 1×
“Abnormalities in the Wnt pathway, not only due to b-catenin mutations, are major events in HCC, and these molecular changes are reliably mirrored by GS overexpression, as recently suggested [20].”
Background
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“Similarly, combinations of different protein markers – HSP70, GPC3, and GS – in 105 hepatocellular nodules performed acceptably (sensitivity and specificity of 72% and 100%, respectively) [120], and were afterwards validated in two larger series [122,123].”
ResultLlovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
“…two of four markers (glypican 3 [GPC3], glutamine synthetase, heat shock protein 70 [HSP70], and clathrin heavy chain) is highly specific for HCC. [131,132] Additional staining can be considered to detect progenitor cell features (K19 and epithelial cellular adhesion molecule) or…”
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Bruix, J., Reig, M., & Sherman, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.041 · Cited by 1,694
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
de Lope, C. R., Tremosini, S., Forner, A., Reig, M., & Bruix, J. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60009-9 · Cited by 610
Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies
Nuciforo, S., Fofana, I., Matter, M. S., Blumer, T., Calabrese, D., Boldanova, T., Piscuoglio, S., Wieland, S., Ringnalda, F., Schwank, G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.001 · Cited by 473
“The same was true for three additional biomarkers commonly used for histological HCC diagnosis, Glypican 3, glutamine synthetase, and heat shock protein 70 (GPC3, GS, andHSP70, respectively) (Di Tommaso et al., 2009) (Figure S1C).”
BackgroundSelf-citationThe biology of Hepatocellular carcinoma: implications for genomic and immune therapies
Khemlina, G., Ikeda, S., & Kurzrock, R. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0712-x · Cited by 464
Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment
Zhou, F., Shang, W., Yu, X., & Tian, J. (2018) · Medicinal Research Reviews · doi:10.1002/med.21455 · Cited by 397
Nault, J. C., Calderaro, J., Di Tommaso, L., Balabaud, C., Zafrani, E. S., Bioulac‐Sage, P., Roncalli, M., & Zucman‐Rossi, J. (2014) · Hepatology · doi:10.1002/hep.27372 · Cited by 354
Self-citationHepatocellular carcinoma: old friends and new tricks
Kim, E., & Viatour, P. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00527-1 · Cited by 307
Histopathology of hepatocellular carcinoma
Schlageter, M., Terracciano, L. M., D’Angelo, S., & Sorrentino, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i43.15955 · Cited by 294
Self-citationHepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
Villanueva, A., Minguez, B., Forner, A., Reig, M., & Llovet, J. M. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.080608.100623 · Cited by 254
Hepatoblastoma and Pediatric Hepatocellular Carcinoma: An Update
Ranganathan, S., Lopez-Terrada, D., & Alaggio, R. (2020) · Pediatric and Developmental Pathology · doi:10.1177/1093526619875228 · Cited by 219
“Immunostaining shows variable GPC3 and GS staining, and b-cat is usually negative for nuclear staining.(32,33) Reticulin pattern is usually lost, unless the tumor is an early HCC.”
BackgroundIntegration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas
Amaddeo, G., Cao, Q., Ladeiro, Y., Imbeaud, S., Nault, J.-C., Jaoui, D., Gaston Mathe, Y., Laurent, C., Laurent, A., Bioulac-Sage, P., et al. (2015) · Gut · doi:10.1136/gutjnl-2013-306228 · Cited by 169
Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications
Safri, F., Nguyen, R., Zerehpooshnesfchi, S., George, J., & Qiao, L. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00764-w · Cited by 162
Liao, H., Xiong, T., Peng, J., Xu, L., Liao, M., Zhang, Z., Wu, Z., Yuan, K., & Zeng, Y. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-019-08190-1 · Cited by 65
Metadata
- Authors
- Di Tommaso, L., Destro, A., Seok, J. Y., Balladore, E., Terracciano, L., Sangiovanni, A., Iavarone, M., Colombo, M., Jang, J. J., Yu, E., Jin, S. Y., Morenghi, E., Park, Y. N., & Roncalli, M.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2009-04
- Volume
- 50
- Issue
- 4
- Pages
- 746-754
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2172145344
- Cited by
- 322
- References
- 18
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.